|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  | | --- | --- | | |  | | --- | |  | | | |  | | --- | |  | | PSNC Newsletter | | Thursday 30th December 2021 | | |  | | |  |  |  | | --- | --- | --- | |  |  |  | |  | This newsletter from PSNC contains important information for those that work in the community pharmacy sector. In this update: LFD stock update; December FP34C submission deadline and medical exemption certificate extension; PhAS 2022 review process.Pharmacy Collect: UKHSA update on LFD stock The unprecedented public demand for Lateral Flow Device (LFD) test kits via the Pharmacy Collect service continues.  The UK Health Security Agency (UKHSA) are continuing to deliver stock to Alliance Healthcare for onward delivery to pharmacies. PSNC has been in regular contact with the UKHSA about the supply issues in recent days and we have the following update for pharmacy teams.   * On 24th December, 2.5 million tests were sent to Alliance Healthcare and that stock was ready to be delivered yesterday (29th December) when Alliance Healthcare re-opened after its planned Christmas break. * Yesterday, a further 2.3m Orient Gene tests were sent to replenish the Alliance Healthcare distribution centres. * Today (30th December), around 1.97m tests (Acon Flowflex and Orient Gene brands) have been sent to Alliance Healthcare. * A similar number of tests is also planned to be delivered to Alliance Healthcare tomorrow (31st December).   Contractors are advised to check availability of each of the available products and order whichever is in stock at the time. There may also be periods when the products appear out of stock, before more replenishment stock is received from the UKHSA; in that circumstance contractors should check back later in the day to see if more stock has become available to order.  [**Read the full story, including a comment from PSNC**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=723cbd05fe&e=d19e9fd41c) Prescription and Reimbursement Notices **December FP34C and bundle submission due by 6th January** As the New Year's Day Bank Holiday (Monday 3rd January 2022) occurs in the FP34C submission window, community pharmacy contractors have been given an extra working day to submit their December FP34Cs and dispatch their prescription bundle to the relevant pricing division at the NHS Business Services Authority (NHSBSA).  [**Find out more about the December submission timetable**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=b7de095b8a&e=d19e9fd41c)  **Extension for medical exemption certificates due to expire** The Department of Health and Social Care (DHSC) has agreed that all medical exemption certificates due to expire between 14th December 2021 and 1st March 2022 will be extended for a further six months from the current date of expiry. New certificates will be issued, but until these arrive, patients are advised to present their letter from the NHSBSA as evidence of exemption.  [**Read more about the exemption certificate extension**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=858045f2e9&e=d19e9fd41c)  **Drug Tariff Watch – January 2022** PSNC's Dispensing and Supply Team has created a summary of the Drug Tariff changes for January 2022. This includes details of additions, deletions and category and price changes.  [**See the January 2022 Drug Tariff Watch**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=724e6ade9c&e=d19e9fd41c) PhAS 2022 review application window opening soon [**The details**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=a4d735f1bc&e=d19e9fd41c) about the revised Pharmacy Access Scheme (PhAS) for 2022 were published earlier this year, with contractors receiving letters from the NHSBSA indicating their eligibility.  At the start of PhAS 2022, a review process allows NHS England and NHS Improvement (NHSE&I) to consider extenuating circumstances which may mean that patient access is not being protected in the way intended by the scheme. The review is based on contractor applications made between January 4th 2022 and midnight on 4th February 2022.  [**Learn more about the PhAS 2022 review process**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=0a9d57e96e&e=d19e9fd41c) |  | |  |  |  | | |
| |  |  |  | | --- | --- | --- | | |  | | --- | | Pharmaceutical Services Negotiating Committee  **[Graphical user interface  Description automatically generated](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=f1d18f6072&e=d19e9fd41c)** **[Graphical user interface  Description automatically generated](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=744cea041c&e=d19e9fd41c)** **[Graphical user interface  Description automatically generated](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=e7977e6864&e=d19e9fd41c)**  14 Hosier Lane, London, EC1A 9LQ Tel: 0203 1220 810 | Email: [**info@psnc.org.uk**](mailto:info@psnc.org.uk) | |  | | |

